REGN

Regeneron develops and commercializes medicines for cancer, eye diseases, and inflammatory conditions, with blockbuster drugs Eylea generating $6 billion annually and Dupixent hitting $11.6 billion in 2023 sales. The company's proprietary VelociSuite platform accelerates drug discovery by producing fully human antibodies in genetically modified mice, giving them a structural advantage in developing safer, more effective treatments. Linvoseltamab, their CD3xBCMA bispecific antibody for multiple myeloma, shows 71% response rates in heavily pre-treated patients and could launch by 2025 with peak sales potential exceeding $3 billion. Trading at 14.3x forward earnings with multiple late-stage assets advancing through trials, REGN offers exposure to both established cash cows and a pipeline that historically converts at twice the industry average. The stock has lagged biotech peers by 15% over the past year despite accelerating Dupixent growth in new indications like COPD.